Pelvic Floor Stimulators Market By Type (Transvaginal pelvic floor stimulators, Transanal Pelvic Floor Stimulators, Transcutaneous Electrical Nerve Stimulators (TENS), Implantable Pelvic Floor Stimulators), By Application (Urinary Incontinence, Pelvic Organ Prolapse (POP), Sexual Dysfunction, Postpartum Rehabilitation, Chronic Pelvic Pain, Others), By End-User (Hospitals & Clinics, Home Care, Rehabilitation Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Pelvic Floor Stimulators market accounted for USD 276.5 Billion in 2024 and is expected to reach USD 924.7 Billion by 2035, growing at a CAGR of around 11.6% between 2025 and 2035.  The pelvic floor stimulator market represents a sector that deals with devices made to stretch or rehabilitate the pelvic floor muscles. The devices make use of electrical stimulation to enhance muscle tone, relieve incontinence, and improve pelvic health.

Pelvic floor stimulators are used in the treatment of conditions such as urinary incontinence, pelvic organ prolapse, and sexual dysfunction. Market segments include medical-grade devices and consumer products. These devices are growing in demand among increasingly aware aging populations and in particular, postpartum women. The main players are closely focused on innovation, user-friendliness, and the scope of treatment options.

Report Scope:

Market Dynamics

Increasing Demand for Non-Invasive Pelvic Floor Stimulators Driven by Growing Awareness

Public awareness of pelvic health issues has driven demand for non-invasive treatments such as pelvic floor stimulators. According to the United States Department of Health and Human Services, pelvic floor disorders - including urinary incontinence and prolapse of the pelvic organ affect an estimated nearly 25 percent of women in the U.S. According to the NIH, over half of all women will experience some form of pelvic health disorder by the time they reach age 80.

The Centers for Disease Control and Prevention report that urinary incontinence affects 13 million Americans most of those women. Such figures indicate the wide prevalence of pelvic health issues. In response, there has been a shift towards non-invasive treatments, and many patients are now seeking devices that include pelvic floor stimulators, which allow a patient to treat pelvic muscles and symptoms non-invasively without the need for surgery. A 2017 study by the National Institutes of Health estimated that nearly 40% of women above the age of 60 have some pelvic floor disorder, further stimulating the need for less invasive procedures.

Aging Population Driving Adoption of Pelvic Floor Stimulators

Driven by the demographic bulge of an aging population, the use of pelvic floor stimulators is so rampant since most elderly individuals tend to develop conditions leading to pelvic floor dysfunction, such as urinary incontinence and pelvic organ prolapse. In 2020, the U.S. Census Bureau reported that 56 million Americans were aged 65 and older. According to the U.S. Department of Health and Human Services, nearly 50% of American women over age 65 experience urinary incontinence.

The condition is a symptom of pelvic floor dysfunction. The Centers for Disease Control and Prevention report the incidence of pelvic floor disorders that increase with age, apparently requiring more non-invasive treatments. With the continually increasing elderly population, there is always the demand for such devices as pelvic floor stimulators that help lessen symptoms efficiently, with no requirement for surgery, making it a readily available and not-so-heavy option for the aged to gain a quality life.

Impact of High Upfront Costs on the Pelvic Floor Stimulator Market

The high upfront price of sophisticated pelvic floor stimulators, especially implantable or high-tech products, acts as a limiting factor for market growth. As estimated by the U.S. Department of Health and Human Services (HHS), cost barriers prevent a significant majority of the population from accessing many needed treatments; nearly 30 percent of people in the U.S. do not receive treatment due to such reasons. Moreover, insurance for such devices can vary significantly.

Policies may not cover the total cost of advanced treatments, which results in the initial high cost preventing patients who would otherwise have benefited from non-invasive pelvic health solutions from adopting them. Patients also incur costs in the long run for such care and follow-up treatments, leading to a greater financial burden. Therefore, some people may choose to spend less money on treatment that may be less effective.

Rising Demand for Wearable Pelvic Floor Stimulators

Increased demand for wearable devices is an opportunity to find innovative solutions to pelvic floor stimulators, providing more discreet, portable, and convenient solutions for continuous use. The U.S. Department of Health and Human Services (HHS) states that one of the fast-growing healthcare industry segments is wearable End-User.

According to the Centers for Disease Control and Prevention, nearly 25 percent of women experience pelvic floor disorders. Thus, there is a huge potential market for wearable pelvic floor stimulators, which carry the advantage of continuous at-home treatment. Patients are well attracted to non-invasive, easy-to-use alternatives to conventional treatments. With telemedicine and digital health platforms gaining prominence, patients can more easily keep up with their condition management from anywhere, a perfect reason for such portable solutions.

Evolving wearable End-User allows a pelvic floor stimulator to be added to an everyday device like a smartwatch, which makes the solution more accessible and convenient for those in need of pelvic health management.

Opportunities for Pelvic Floor Stimulators in Postpartum Homecare

There is huge market growth potential for pelvic floor stimulators when the need arises for postpartum women in their homecare settings. According to the Centers for Disease Control and Prevention (CDC), which reported that 3,667,758 babies were born in the United States in 2022, up to 50% of all postpartum women may experience pelvic floor disorders, including urinary incontinence and pelvic organ prolapse.

The U.S. Department of Health and Human Services acknowledges that a growing number of new mothers want less intrusive solutions to their post-partum recovery, preferably at home. The pelvic floor stimulator is a very effective home-use device for maintaining the strengthening of the pelvic muscles by postpartum women with minimal visits to the clinic.

The device is also important in finding a critical gap within the care system as more women become aware of postpartum pelvic health issues, thereby facilitating rapid recovery and long-term health management. Such products cater to the ongoing increased trend in demand for in-home care, particularly following the COVID-19 pandemic.

Industry Experts Opinion

“InTone is a true medical breakthrough, and welcome news for the millions of women who have incontinence issues,”

• Herschel "Buzz" Peddicord, President and CEO of InControl Medical.

Segment Analysis

Based on treatment type, intravaginal stimulants, TENS devices, wearable devices, and implantable stimulators offer various pelvic floor support options. Implantable stimulators are often considered the most effective for severe cases due to their long-term, targeted support.

Based on application, devices treat urinary incontinence, pelvic organ prolapse, sexual dysfunction, postpartum recovery, chronic pelvic pain, and other pelvic floor issues. Among these, devices for urinary incontinence are often the most widely used due to the commonality and impact of the condition.

Based on end-user, devices are used in hospitals and clinics for advanced care, home care for private management, and rehabilitation centers for specialized pelvic floor recovery. Home care solutions are increasingly popular due to their convenience and effectiveness for everyday use.

Regional Analysis

North America is the leading market for pelvic floor stimulators, primarily due to strong awareness, well-developed healthcare infrastructure, and the increasing prevalence of pelvic disorders such as urinary incontinence and sexual dysfunction. A significant number of major manufacturers of pelvic floor stimulators are operational in this region along with favorable reimbursement policies and advanced technologies which support their adoption.

Additionally, preventive healthcare and patient-centered solutions are gaining emphasis, and are contributing to increased applications for pelvic floor stimulators in North America. The shift towards home-based healthcare solutions is one of the key aspects that contributes to market growth in the region.

European demand for pelvic floor stimulators is among the fastest-growing regions. Germany, the UK, and France are increasingly looking for non-invasive pelvic floor stimulator and technological innovations in pelvic health. An aging population combined with an increasing focus on women's health has significantly boosted the demand for pelvic floor solutions. In addition, Europe is witnessing growth in the market through government initiatives, with innovations in healthcare and the increased popularity of home care devices among patients.

The present movement towards digital health solutions is also pushing for what was considered too complex before the personalization and convenience of treatments. There is a growing awareness of pelvic health issues, which is increasing the demand for proactive treatment. The rapid growth in the accessibility of telehealth services also further enhances access to care and widens the market.

Competitive Landscape

The competitive landscape of the pelvic floor stimulators market is dominated by quite a few major players, such as Medtronic, Boston Scientific Corporation, Axonics Modulation Technologies, and AbbVie Inc. These are leading market players with advanced technologies and innovative solutions to prevent pelvic floor disorders. Recent developments, like the approval of Axonics' Sacral Neuromodulation System, aptly reflect the growing trend toward minimal-invasive treatments.

Medtronic also expanded its pelvic health portfolio with new launches that would be used to treat a more comprehensive range of pelvic floor disorders. The market is also observing digital health solutions. Companies like Stimwave are currently exploring wireless, implantable devices to create more patient-friendly convenience and outcomes. Research and the quest for product development continue to fuel growth and competition in this sector.

Pelvic Floor Stimulators Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In July 2024, Axena Health announced that two major health plans in Pennsylvania and North Dakota added the Leva Pelvic Health System to their covered benefits for urinary incontinence. This move expands patient access and could boost sales and revenue for the company.
• In March 2024, Nissrine Nakib, MD, and Lydia Zeller discussed the Therapeutic Advances in Urology study on Pelvital’s Flyte intra-vaginal device for stress urinary incontinence treatment.
• In February 2022, Medtronic announced FDA approval for the InterStim X™, a recharge-free device for treating overactive bladder, fecal incontinence, and urinary retention, backed by 25 years of clinical experience.

Report Coverage:

By Type

• Transvaginal pelvic floor stimulators
• Transanal Pelvic Floor Stimulators
• Transcutaneous Electrical Nerve Stimulators (TENS)
• Implantable Pelvic Floor Stimulators

By Application

• Urinary Incontinence
• Pelvic Organ Prolapse (POP)
• Sexual Dysfunction
• Postpartum Rehabilitation
• Chronic Pelvic Pain
• Others

By End-User

• Hospitals & Clinics
• Home Care
• Rehabilitation Centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Medtronic
• Boston Scientific Corporation
• AbbVie Inc.
• Cochlear Limited
• Neuspera Medical, Inc.
• Pfizer Inc.
• InControl Medical
• Innovative Medical Products, Inc.
• Uroplasty, Inc.
• Axonics Modulation Technologies, Inc.
• Teneo Technologies
• Stimwave, LLC
• Zyga End-User, Inc.
• Civco Medical Instruments
• EndoStim, Inc.

Frequently Asked Questions (FAQs)